Loading...
Loading...
ARIAD Pharmaceuticals, Inc.
today announced its schedule of
preclinical data presentations to be made at the American Association for
Cancer Research (AACR) Annual Meeting 2013, taking place Saturday, April 6
through Wednesday, April 10, 2013, in Washington.
Listed below are the details of presentations at AACR that describe ARIAD's
product candidates. There will be four presentations of data on ARIAD's
targeted therapies, Iclusig™ (ponatinib) and AP26113; and one invited talk:
Title: Ponatinib is a highly potent inhibitor of activated variants of RET
found in MTC and NSCLC
Date & Time: Monday, April 8, 1:00–5:00 p.m. (Poster)
Abstract: #2084
Location: Hall A-C, Poster Section 38
Title: Ponatinib potently inhibits the activity of mutant variants of FGFR
commonly found in endometrial, lung and other cancers
Date & Time: Monday, April 8, 1:00–5:00 p.m. (Poster)
Abstract: #2083
Location: Hall A-C, Poster Section 38
Title: Ponatinib, a pan-BCR-ABL inhibitor, potently inhibits key activating
and drug-resistant KIT mutants found in GIST
Date & Time: Tuesday, April 9, 8:00 a.m.–12:00 p.m. (Poster)
Abstract: #3394
Location: Hall A-C, Poster Section 42
Title: Design and development of ponatinib, a pan-BCR-ABL inhibitor for CML
Date & Time: Tuesday, April 9, 9:30–10:00 a.m. (Major symposium)
Presentation: #SY19-04
Location: Salon A-B, East Hall
Title: AP26113 possesses pan-inhibitory activity versus crizotinib-resistant
ALK mutants and oncogenic ROS1 fusions
Date & Time: Wednesday, April 10, 8:00 a.m.–12:00 p.m. (Poster)
Abstract: #5655
Location: Hall A-C, Poster Section 42
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in